Tomaszewska, A, Basak, GW, Peczynski, C, Polge, E, Ambron, P, Boreland, W, Sica, S, Arat, M, Passweg, J, Lorenzo, JLL, Salmenniemi, U, Jindra, P, Kulagin, A, Bufarull, RM, Eder, M, Bekadja, MA, Mussetti, A, Graham, CE, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working Party. Cancers. 2025; 17(24)DOI:10.3390/cancers17244029. PMID:41463278. IF:4.400(Q2/3D).

Alós, DG, Sanchez, S, Dominguez, SR, Magnano, L, Barca, EG, Vicente, FD, Iacoboni, G, Manso, RG, Losada, CM, Huerga, S, Baumann, T, Izquierdo, AR, Bacelar, AG, Santaella, MP, Prieto, PG, De Villambrosia, SG, Bastos-Oreiro, M, Hernandez, AC, De Miguel, LB, Abellan, PF, Sturla, AL, Vidaller, PJP, Amutio, E, Toimil, FS, Pra, AM, Mico, M, De La Mano, EP, De La Cruz, B, Browne, S, Landwehr, M, Hernandez, I, Andreu, R, De La Cruz, J, Ubieto, AJ. Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group. BLOOD. 2025; 146DOI:10.1182/blood-2025-472. PMID:. IF:23.100(Q1/1D).

Moya, TA, Gay, MQS, Pasic, I, Gonzalez, MB, Gómez, MA, Salinas, AS, Camacho, JS, Alvaro, VI, Abdallah-Lefdil, Z, Navascues, JC, Gambarte, LP, Fernandez-Luis, S, Vega, L, Villar, S, Murillo, PB, Esquirol, A, Garcia, II, Mussetti, A, Lavilla-Rubira, E, Lopez, J, Filafferro, S, Balsalobre, P, Miguel, LBD, Michelis, F, Viswabandya, A, Mattsson, J, Alibhai, S, Rovira, M, Kim, D, Balari, AS, Kumar, R. Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients. BLOOD. 2025; 146DOI:10.1182/blood-2025-2652. PMID:. IF:23.100(Q1/1D).

Kroeger, N, Sanz, J, Stelljes, M, Martino, R, Rambaldi, A, Kwon, M, Sanchez-Guijo, F, Markova, M, Bondarenko, S, Eder, M, Heuser, M, Solano, C, Bonifazi, F, Wohlfarth, P, Massoud, R, Ayuk, F, Clausen, J, Choi, G, Greinix, H, Chiusolo, P, Patriarca, F, Gagelmann, N, Busca, A, Bug, G, Schroeder, T, Bethge, W, Glöckner, A, Hoelzer, D, Zey, S, Buchner, H, Wolschke, C. Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis-a randomized prospective european trial. BLOOD. 2025; 146DOI:10.1182/blood-2025-171. PMID:. IF:23.100(Q1/1D).

Westin, J, Chavez, J, Schuster, SJ, Vucinic, V, Young, PA, Johnson, PC, Bramanti, S, Rambaldi, A, Meijide, JB, Kato, K, Sancho, JM, Kwon, M, Solano, C, Fleming, S, Dahiya, S, Garcia-Sancho, AM, Ramos, PM, Pearson, D, Diallo, S, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results. BLOOD. 2025; 146DOI:10.1182/blood-2025-670. PMID:. IF:23.100(Q1/1D).

Barba, P, Rambaldi, A, Boissel, N, Doki, N, Blaise, D, Ciceri, F, Meijide, JB, Kwon, M, Fleming, S, Goñi, CB, Teshima, T, Kato, K, Balsat, M, Jaeger, U, Shune, L, Ramos, PM, Pearson, D, Corcoran, J, Zia, A, Foster, M, Masood, A, Dickinson, M. Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). BLOOD. 2025; 146DOI:10.1182/blood-2025-811. PMID:. IF:23.100(Q1/1D).

Munárriz, D, Pérez-Lopez, E, Rodríguez, CM, Luque, M, Esquirol, A, Calvo, CM, Aparicio, C, Peña-Muñoz, F, Fernando, IH, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Lopez-Lorenzo, JL, Fleitas, CA, González-Rodriguez, AP, García, L, Torrado, T, Filaferro, S, Balsalobre, P, Cascon, MJP, Rovira, M, Salas, MQ. Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC. Frontiers in Immunology. 2025; 16DOI:10.3389/fimmu.2025.1700463. PMID:41394844. IF:5.900(Q1/2D).

Torres-Esquius, S, Gabarros-Subira, M, Gurnari, C, Bravo-Perez, C, López, GR, Arias, RD, Sanz, A, Martinez, MM, Beas, F, Jáuregui, SN, Arias, R, Canela, MP, Saumell, S, Voso, MT, Maciejewski, J, Acha, P, Valcarcel, D, Jerez, A, Montoro, MJ. Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy. BLOOD. 2025; 146DOI:10.1182/blood-2025-4997. PMID:. IF:23.100(Q1/1D).

Ubieto, AJ, Alós, DG, Dominguez, SR, Magnano, L, Sánchez, S, Vicente, FD, Iacoboni, G, Losada, CM, Manso, RG, Browne, S, Izquierdo, AR, Baumann, T, Bacelar, AG, Santaella, MP, Prieto, PG, De Villambrosia, SG, Bastos-Oreiro, M, Hernandez, AC, De Miguel, LB, Sturla, AL, Abellan, PF, Vidaller, PJP, Amutio, E, Toimil, FS, Pardal, E, Micó, M, Prat, AM, De La Cruz, B, Huerga, S, Landwehr, M, Hernández, I, Andreu, R, De la Cruz, J, Barca, EG. First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO). BLOOD. 2025; 146DOI:10.1182/blood-2025-3677. PMID:. IF:23.100(Q1/1D).

Gurnari, C, Ottone, T, Piciocchi, A, Späth, D, Meid, A, Marsili, G, Fabiani, E, Romano, F, Pascale, MR, Chiusolo, P, Di Ianni, M, Sobas, M, Brunetti, L, Oñate, G, Infante, JB, Nanni, J, Vetro, C, Boada, M, Candoni, A, Sierra, J, Potter, N, Gilkes, A, Johnson, S, Thomas, I, Huntley, B, Russell, N, Dillon, R, Döhner, H, Döhner, K, Voso, MT. Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG). BLOOD. 2025; 146DOI:10.1182/blood-2025-217. PMID:. IF:23.100(Q1/1D).

Hernández-Rivas, JA, Prat, AM, Ponce, ES, Medina, A, Lluch-García, R, Oliveira, ACD, Rodriguez-Fernandez, A, Soler, JA, Terol-Castera, MJ, Machado-Machado, P, Pérez-Encinas, M, Romero-Carmona, R, Segundo, LYS, García-Martin, P, Mompo, C, Zubillaga-Marban, E. First worldwide real-life data on fixed-duration ibrutinib plus venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain's LI plus VE observational study. BLOOD. 2025; 146DOI:10.1182/blood-2025-2728. PMID:. IF:23.100(Q1/1D).

Niebla, AM, Gine, E, Bastos-Oreiro, M, Perez, A, Cabirta, A, Vicente, FD, Vilaseca, MC, Ubieto, AJ, De Villambrosia, SG, Prat, AM, Barca, EG, Henriquez, HDL, Herranz, ER, Prieto, PG, Cordoba, R, Carreres, AS, Garcia-Sancho, AM, Moya, AMGN, Grande, C, Martine, PP, Nicolas, C, Gutierrez, A, Rivas, JAH, Sanchez-Gonzalez, B, Villalobos, MT, Garcia-Cerecedo, T, Trillo, RA, Donato, E, Gutierrez, PV, Belmonte, DG, Cozzarelli, SRV, Ordoñez, SS, De La Mano, EP, Avaría, A, Blanco, LV, Roldan-Perez, A, Sancho, JM, De la Cruz, B, Prince-Eladnani, R, Abrisqueta, P. Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study. BLOOD. 2025; 146DOI:10.1182/blood-2025-3592. PMID:. IF:23.100(Q1/1D).

Chatzikonstantinou, T, Agathangelidis, A, Talimtzi, P, Laidou, S, Minga, E, Roussos, A, Angelopoulou, M, De Tomas, MA, Antic, D, Baran-Marszak, F, Bödör, C, Albareda, FB, Catherwood, M, Chatzileontiadou, S, Chessa, C, Coscia, M, Crespo, M, Cuneo, A, Davis, Z, Dimou, M, Doubek, M, Efstathopoulou, M, Espinet, B, Gaidano, G, Gupta, R, Hatzimichael, E, Herishanu, Y, Karamanli, T, Konstantinou, E, Kotsianidis, I, Koumpis, AE, Laszlo, T, Levy, V, Machairas, A, Martini, F, Moia, R, Mouhssine, S, Prat, AM, Murru, R, Mpalaoura, E, Pangalis, G, Papaioannou, M, Pavlova, S, Plevova, K, Pospisilova, S, Puiggros, A, Rani, L, Rigolin, GM, Romano, I, Rossi, D, Serna, A, Simkovic, M, Smolej, L, Stavrogianni, N, Vujovic, KT, Trentin, L, Vassilakopoulos, T, Visentin, A, Vitale, C, Vrachiolias, G, Scarfo, L, Chatzidimitriou, A, Ghia, P, Stamatopoulos, K. Dissecting the heterogeneity of IGHV-mutated CLL: An eric study. BLOOD. 2025; 146DOI:10.1182/blood-2025-2120. PMID:. IF:23.100(Q1/1D).

Bastos-Oreiro, M, Cabirta, A, Perez, A, Carreres, AS, De Villambrosia, SG, Canelo, M, Moya, AMGN, Benito, BD, Gutiérrez, PV, Vicente, FD, Caballero, JC, Jiménez-Ubieto, A, Belmonte, DG, Prat, AM, Barca, EG, Henríquez, HDL, Herranz, ER, Garcia-Sancho, AM, Grande, C, Nicolás, C, Gutierrez, A, Gomez-Llobell, M, Rivas, JAH, Sánchez-González, B, Campos, AF, Trillo, RA, Donato, E, Cozzarell, SRV, Ordoñez, SS, De La Mano, EP, Prieto, PG, Avaria, A, Blanco, LV, Roldán-Pérez, A, Cordoba, R, Sancho, JM, Gine, E, Garces, VN, Abrisqueta, P, Niebla, AM. Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group. BLOOD. 2025; 146DOI:10.1182/blood-2025-3585. PMID:. IF:23.100(Q1/1D).

Gabarros-Subira, M, Torres-Esquius, S, Pomares, H, Beas, F, Suárez-Gonzalez, J, Sanchez, AH, Lopez-Fernandez, E, López, GR, Hermosin-Ramos, M, Carreño, G, Castillo, IM, García, JD, Santiago, M, Pascual, M, Díaz-Beyá, M, Carrascosa, GB, Montoya, RT, Ortuño, FJ, Vives, S, Mañó, LG, Casares, MTG, Alfonso-Pierola, A, Pris-Vilaespesa, M, Revilla, N, Alonso, S, Iborra, A, Lores, BF, Díaz, RMA, Cervera, J, Corral, LL, Canela, MP, Buño, I, Montoro, MJ, Hernandez, F, Albareda, FB, Arnan, M, Valcarcel, D, Martinez-Laperche, C, Jerez, A. Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers. BLOOD. 2025; 146DOI:10.1182/blood-2025-4275. PMID:. IF:23.100(Q1/1D).

Riedell, PA, Kwon, M, Flinn, IW, Dickinson, MJ, Solano, C, Jaeger, U, Briones, J, Kato, K, Fleming, S, Bachy, E, Rambaldi, A, Shune, LO, Shah, NN, Blaise, D, Frigault, MJ, Ramakrishnan, A, Yang, A, Pearson, D, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Wei, AH, Reyner, JE, Garciaz, S, Aldoss, I, Piérola, A, Allred, A, Dominguez, JMA, Barreyro, L, Bories, P, Daskalakis, N, Porta, MGD, Döhner, H, D'Souza, A, Dugan, J, Fathi, A, Fedele, P, Ferrante, L, Kobos, R, Gaj, S, Diaz, AG, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jabbour, E, Trancucci, D, Bamidele, T, Jentzsch, M, Kantarjian, H, Konopleva, M, Krönke, J, Hütter-Krönke, ML, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Morillo, D, O'Nions, J, Packman, K, Papayannidis, C, Récher, C, Roellig, C, Salamero, O, Nagarajahastri, P, Sauer, T, Searle, E, Tovar, N, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Platzbecker, U. Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax plus Azacitidine (VEN plus AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/ Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Jabbour, E, Recher, C, O'Nions, J, Aldoss, I, Pierola, A, Allred, A, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Curtis, M, Daskalakis, N, Della Porta, MG, Döhner, H, D'Souza, A, Dugan, JP, Reyner, JE, Exum, M, Fathi, AT, Fedele, PL, Ferrante, L, Gaj, S, Garciaz, S, Garrido, A, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Kwon, MC, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Martinelli, G, Giles, DM, Murphy, J, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Rangaraju, S, Röllig, C, Salamero, O, Sanga, M, Sauer, T, Searle, E, Tovar, N, Tucker, T, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Wei, A. Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Borrell-Pichot, M, Lozano, A, Granell, E, Caballero, A, Briones-Mejide, J, Caballero-Avila, M, Vidal-Jordana, A, Querol, L, Mart n-Aguilar, L. Regression of pre-existing white matter hyperintensities after CD19 CAR Tcell induced ICANS: A case series. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Cortés-Bullich, A, Guijarro, F, Jiménez-Vicente, C, Bataller, A, Martínez-Roca, A, Triguero, A, Guerra, ML, Castaño-Diez, S, Oñate, G, Díaz-Beyá, M, Pich-Roselló, O, Esteve, J. RNA-Seq analysis of the tumor microenvironment reveals prognostic subgroups in Acute Myeloid Leukemia with myelodysplasia-related gene mutations. ANNALS OF HEMATOLOGY. 2025; 104(1)DOI:. PMID:. IF:2.400(Q2/5D).